List of Excipients in Branded Drug YASMIN

Yasmin Excipient Strategy and Commercial Opportunities: Formulation, Generic Competition, and IP Analysis

Last updated: September 1, 2026

Yasmin is an oral combined hormonal contraceptive containing 3 mg drospirenone and 0.03 mg ethinyl estradiol. Its US formulation uses conventional tablet excipients, including lactose monohydrate, corn starch, magnesium stearate, povidone, hypromellose, talc, titanium dioxide, and ferric oxide yellow.[1] The product has no meaningful current exclusivity barrier based on the active ingredients or standard excipient system. Commercial opportunities therefore center on lower-cost generic manufacture, differentiated excipient systems, improved packaging and stability, and alternative drospirenone/ethinyl estradiol delivery formats.

What is Yasmin and which excipients does it contain?

Yasmin is Bayer's branded oral contraceptive tablet. Each active tablet contains:

Component	Amount per tablet	Function
Drospirenone	3 mg	Progestin
Ethinyl estradiol	0.03 mg	Estrogen
Lactose monohydrate	Not publicly quantified	Diluent and tablet filler
Corn starch	Not publicly quantified	Disintegrant and binder
Povidone	Not publicly quantified	Binder
Magnesium stearate	Not publicly quantified	Lubricant
Hypromellose	Not publicly quantified	Film-coating polymer
Talc	Not publicly quantified	Coating aid and anti-adherent
Titanium dioxide	Not publicly quantified	Opacifier and colorant
Ferric oxide yellow	Not publicly quantified	Colorant

The exact quantitative composition is generally proprietary. FDA labeling identifies inactive ingredients but does not disclose the complete manufacturing formula or process parameters.[1]

Yasmin tablets are film-coated, orally administered, and designed for daily use. The formulation does not depend on an unusual controlled-release excipient, lipid system, complexation technology, or specialized drug-delivery platform.

What formulation strategy does Yasmin use?

Yasmin uses a conventional immediate-release, film-coated tablet strategy. The formulation priorities are content uniformity, mechanical integrity, rapid disintegration, dissolution, chemical stability, and reproducible high-volume manufacturing.

Role of the core excipients

Lactose monohydrate provides bulk in a low-dose tablet. Because the combined active load is only 3.03 mg, the formulation requires a substantial carrier phase to achieve manufacturable tablet weight and acceptable content uniformity.

Corn starch supports tablet breakup after ingestion and can contribute to granulation performance. Povidone improves particle binding during wet or dry granulation. Magnesium stearate reduces tooling adhesion and ejection force but requires controlled blending because excess lubrication can slow disintegration or dissolution.

The hypromellose, talc, titanium dioxide, and ferric oxide yellow system forms the film coat and provides the product's visual identity. The coating can also reduce handling damage and provide a modest barrier against environmental exposure.

Why the low active dose matters

Yasmin's low active load creates a technical risk that is different from that of high-dose tablets. A small absolute variation in the active ingredients can produce a comparatively large percentage variation. Blend uniformity, segregation control, and sampling design are therefore important manufacturing variables.

Drospirenone and ethinyl estradiol also have different physicochemical properties. A generic manufacturer must establish a robust distribution of both actives throughout the blend and demonstrate dissolution equivalence under the applicable regulatory pathway.

What patents protect Yasmin?

The principal patent opportunity for Yasmin is no longer the original composition. The active ingredients and conventional excipients are now exposed to generic competition in major markets.

IP category	Yasmin relevance	Current commercial effect
Drospirenone composition patents	Historically important	Foundational protection has expired or is no longer a practical barrier in major generic markets
Ethinyl estradiol use patents	Limited product-level protection	Historical method-of-use claims generally do not block standard contraceptive substitution
Combination-product patents	Relevant to launch timing historically	No longer a durable barrier to conventional generic tablets
Film-coating composition	Usually low-value	Common materials are readily substitutable
Manufacturing-process patents	Potentially relevant to a specific supplier	Can affect freedom to operate if a process is unusually narrow or actively enforced
Packaging and stability technology	Commercially relevant	More likely to protect product quality than market exclusivity
New delivery systems	Potentially valuable	May support new patent filings for extended release, implants, rings, or transdermal products

FDA Orange Book treatment should be distinguished from general patent history. Orange Book-listed patents can affect an abbreviated new drug application through Paragraph IV certification, but an excipient listed in the Yasmin label does not itself create product exclusivity.[2]

When does Yasmin lose exclusivity?

Yasmin has already lost practical market exclusivity in the United States and other major regulated markets. The original product was approved in the United States in 2001.[1] Generic drospirenone/ethinyl estradiol products have entered the market, including products marketed under names such as Ocella, Gianvi, and generic drospirenone and ethinyl estradiol tablets.

The commercial sequence was:

Period	Market event
2001	FDA approval of Yasmin in the United States
2000s	Expansion of Bayer's contraceptive franchise and development of related drospirenone products
Late 2000s onward	Generic competition in drospirenone/ethinyl estradiol tablets
2010s	Wider substitution by generic products and lower-priced branded generics
Current market	Mature, price-sensitive oral contraceptive category

Yasmin's brand value remains relevant for prescribing recognition, pharmacy substitution dynamics, and international markets. It does not create a strong barrier against a conventional ANDA product.

What generic entry risks exist for Yasmin?

Generic entry risk is high because the product has several characteristics that support replication:

1. The dosage form is a standard immediate-release tablet.
2. The excipients are common pharmaceutical-grade materials.
3. The active ingredients are available from multiple qualified suppliers.
4. The product does not depend on a proprietary delivery device.
5. The active ingredients are administered at low quantities that are compatible with established oral-solid-dose manufacturing platforms.
6. The market has a long history of generic substitution.

The key technical risks for a generic applicant are not access to excipients. They are bioequivalence, content uniformity, dissolution, impurity control, stability, and manufacturing reproducibility.

Paragraph IV challenges

A Paragraph IV certification is relevant only when an ANDA applicant challenges an unexpired patent listed in the Orange Book. For a mature Yasmin tablet, the principal patent risk has historically been timing and certification strategy rather than a durable excipient patent.

A generic applicant may face:

• A 30-month stay if the patent holder files an infringement action within the statutory period.
• Delayed launch from settlement terms.
• At-risk launch exposure if litigation remains unresolved.
• Product-specific requirements for labeling, indications, and inactive ingredients.
• State-level substitution and pharmacy-channel restrictions.

The original Yasmin excipient system is unlikely to provide a meaningful Paragraph IV defense. A new generic formulation could use different fillers, binders, disintegrants, lubricants, and coating colors if it meets regulatory requirements and does not infringe an active claim.

What formulation patents could protect a next-generation Yasmin product?

The strongest future patent opportunities are unlikely to involve lactose, starch, or magnesium stearate alone. Those materials are established excipients with broad prior art. More defensible claims could target a complete formulation architecture or a new delivery system.

Potential formulation patent areas

Improved stability

A formulation patent could claim a defined impurity profile or a composition that limits degradation of drospirenone or ethinyl estradiol under heat, humidity, or light stress. The value would depend on demonstrated superiority over standard tablets.

Possible technical approaches include:

• Moisture-controlled granulation
• Protective film coatings
• Antioxidant or chelating systems, where compatible with the actives
• Low-permeability blister packaging
• Defined water activity limits
• Specific particle-size distributions
• Controlled residual solvent or process-water specifications

Modified release

An extended-release drospirenone/ethinyl estradiol product could seek to reduce peak-to-trough exposure or support a different dosing schedule. This would require clinical and regulatory development beyond a conventional generic pathway.

Modified-release opportunities may include:

• Matrix tablets
• Osmotic delivery
• Multiparticulate systems
• Gastroretentive products
• Long-acting implants
• Vaginal rings
• Transdermal systems

The patent value would come from the release profile, pharmacokinetic performance, clinical effect, or delivery device, not from the presence of a routine binder or lubricant.

Excipient substitution

A lactose-free product could target patients with lactose sensitivity, supply-chain resilience, or specific manufacturing preferences. Candidate systems could include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or directly compressible starch.

A substitute-excipient formulation would need to maintain:

• Active uniformity
• Tablet hardness
• Friability performance
• Disintegration and dissolution
• Stability
• Bioequivalence
• Acceptable tablet size and swallowability

The commercial differentiation would be stronger if the substitution solves a documented quality, supply, or patient-use problem.

What excipient strategy is best for a Yasmin generic?

The optimal strategy for a conventional generic is cost control with low regulatory complexity. A manufacturer should normally prefer well-characterized, widely sourced excipients unless a differentiated product claim justifies added development cost.

Strategic objective	Preferred excipient approach
Lowest manufacturing cost	Lactose-starch or microcrystalline-cellulose system using standard equipment
Lactose-free positioning	Microcrystalline cellulose, mannitol, or phosphate-based filler system
Direct compression	Highly compressible filler with optimized flow and lubricant level
Wet granulation	Starch and povidone system with controlled granule size
Better moisture resistance	Lower-moisture excipients, protective coating, high-barrier packaging
Global supply resilience	Dual-source excipients with compendial equivalence
Premium patient positioning	Smaller tablet, color-free coating, lactose-free composition, or packaging convenience
Manufacturing simplification	Direct-compression platform, if blend uniformity and dissolution are acceptable

The lowest-risk route is often a formulation that remains close to the reference product's performance while changing nonessential excipients. A larger formulation departure can create additional bioequivalence and scale-up work.

What commercial opportunities exist beyond a standard generic?

Low-cost generic tablets

This is the largest immediate opportunity, but it is also the most competitive. Margins are constrained by pharmacy benefit managers, government reimbursement, tender purchasing, and multiple suppliers.

A successful entrant needs:

• Reliable active-ingredient sourcing
• High batch yields
• Low tablet weight variability
• Competitive packaging cost
• Adequate shelf life
• Stable regulatory supply
• Efficient distribution through wholesalers and retail pharmacies

Lactose-free and excipient-sensitive products

A lactose-free version could support a differentiated product claim, although the addressable population is narrower than the total contraceptive market. The commercial value would depend on clear labeling, physician awareness, pharmacy availability, and pricing discipline.

The product should avoid overstating the benefit. Lactose in a tablet is generally present in a much smaller quantity than dietary lactose exposures, and the clinical relevance varies by patient.

Supply-chain-resilient products

Excipient sourcing is a potential commercial advantage where manufacturers face shortages, geopolitical restrictions, or reliance on a single supplier. A dual-source formulation can reduce supply risk, but the change-control burden must be managed carefully.

The most practical strategy is to qualify multiple suppliers for the same excipient grade rather than rely on a novel material with limited regulatory history.

Alternative dosage forms

A long-acting drospirenone/ethinyl estradiol product could create more defensible intellectual property and improve adherence. It would also require substantially higher investment, clinical evidence, device development, and regulatory work.

Potential products include:

• Vaginal rings
• Transdermal patches
• Subcutaneous implants
• Monthly or quarterly injectable formulations
• Extended-cycle oral regimens

These products would compete with existing long-acting contraceptives, including levonorgestrel intrauterine systems, etonogestrel implants, and depot medroxyprogesterone products. The commercial case would depend on whether drospirenone's clinical profile supports a meaningful patient or prescriber advantage.

How does Yasmin compare with Yaz and other drospirenone products?

Product	Drospirenone	Ethinyl estradiol	Commercial distinction
Yasmin	3 mg	0.03 mg	Standard 21 active-tablet combined oral contraceptive regimen
Yaz	3 mg	0.02 mg	Lower estrogen dose and different regimen
Generic Yasmin equivalents	3 mg	0.03 mg	Price-led substitution
Drospirenone-only products	Product-specific	None	Different clinical positioning and safety profile

Yasmin and Yaz should not be treated as interchangeable development targets. Their ethinyl estradiol strengths, dosing regimens, labeling, bioequivalence requirements, and commercial positioning differ.

For an excipient supplier, the products may share a platform, but each finished dosage form requires product-specific formulation and regulatory documentation.

What manufacturing and IP barriers affect a Yasmin opportunity?

The manufacturing barrier is moderate for a qualified oral-solid-dose manufacturer and low for a company with an established hormonal-product platform. The active ingredients require controlled handling, validated analytical methods, and impurity monitoring. Hormonal products also require appropriate containment and cleaning validation to prevent cross-contamination.

Key barriers include:

• Active-ingredient qualification
• Potency and content-uniformity control
• Hormone-containment procedures
• Cleaning validation
• Cross-contamination prevention
• Dissolution matching
• Stability in commercial packaging
• Regulatory documentation for inactive ingredients
• Country-specific product registration
• Pharmacovigilance and labeling compliance

IP barriers are weaker for a conventional Yasmin-equivalent tablet than for a new delivery system. A new formulation can create a stronger patent position only if it contains a specific, non-obvious technical solution supported by comparative data.

What is the FDA regulatory status and Orange Book position?

Yasmin is an FDA-approved prescription oral contraceptive.[1] Generic applicants generally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. The inactive ingredients do not need to be identical, but they must be suitable for the dosage form and compatible with the applicable regulatory requirements.

The Orange Book is the controlling FDA source for reference-listed-drug status, patent listings, exclusivity, and therapeutic-equivalence information.[2] A current commercial decision should distinguish:

• The reference listed drug
• Approved ANDAs
• Any active listed patents
• Any exclusivity periods
• Therapeutic-equivalence ratings
• Labeling differences
• Marketed versus approved products

For a mature product such as Yasmin, the likely commercial issue is product economics and supply reliability rather than FDA exclusivity.

Which companies are challenging or competing with Yasmin?

Competition comes from several groups:

• Generic manufacturers of drospirenone/ethinyl estradiol tablets
• Branded generic suppliers
• Other combined oral contraceptive manufacturers
• Drospirenone-only product developers
• Long-acting contraceptive manufacturers
• Digital and specialty contraception providers that influence product selection and adherence

The competitive landscape is fragmented. Price, formulary access, pharmacy availability, packaging, patient support, and supply continuity are more important than a proprietary excipient system for the standard tablet market.

What is the revenue exposure and commercial outlook?

Yasmin's direct brand revenue is exposed to generic substitution. The larger strategic value lies in the broader drospirenone franchise, lifecycle management, international brands, and differentiated hormonal delivery systems.

Opportunity	Revenue potential	Development burden	IP strength
Conventional generic tablet	Low to moderate per unit, high volume	Low to moderate	Low
Lactose-free tablet	Moderate niche potential	Moderate	Low to moderate
Premium packaging and adherence format	Moderate	Moderate	Moderate
Extended-release tablet	High if clinically differentiated	High	Moderate to high
Vaginal ring or patch	High potential	Very high	High if technically novel
Drospirenone-only product	Product-specific	High	Moderate to high

The most attractive near-term opportunity is an efficient, supply-secure generic platform. The strongest long-term opportunity is a clinically differentiated delivery system with new composition, device, or method-of-use claims.

Key Takeaways

• Yasmin contains drospirenone 3 mg and ethinyl estradiol 0.03 mg.
• Its US label identifies conventional excipients, including lactose monohydrate, corn starch, povidone, magnesium stearate, hypromellose, talc, titanium dioxide, and ferric oxide yellow.
• The standard excipient system is unlikely to provide meaningful current market exclusivity.
• Generic entry risk is high because Yasmin is a conventional immediate-release tablet with common excipients.
• The best generic strategy is cost-efficient manufacturing with robust blend uniformity, dissolution, stability, and supply continuity.
• Lactose-free formulations and improved moisture-protection systems offer niche differentiation.
• Stronger future patent positions would likely require modified release, alternative delivery systems, stability technology, or a clinically meaningful method of use.
• Yasmin, Yaz, and drospirenone-only products require separate formulation, regulatory, and commercial analyses.
• The principal current barriers are manufacturing control, bioequivalence, regulatory compliance, and market access rather than foundational composition patents.

FAQs

Can a generic Yasmin product use different excipients?

Yes. An ANDA product can use different inactive ingredients if they are appropriate for the dosage form and the product meets pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements.

Is lactose in Yasmin a major patent or regulatory barrier?

No. Lactose is a conventional diluent and does not ordinarily create meaningful product exclusivity. A manufacturer can develop a lactose-free formulation using alternative fillers.

Can an excipient supplier patent a new Yasmin formulation?

Potentially, but a patent would require a novel and non-obvious composition or process. A routine substitution of lactose with another standard filler is unlikely to provide strong protection without demonstrated technical advantages.

Does Yasmin have biosimilar risk?

No. Yasmin is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive pathway is the generic drug pathway, primarily through an ANDA in the United States.

What packaging is most relevant for a Yasmin generic?

High-barrier blister packaging is commercially relevant because it can support stability, protect tablets from moisture and light, and improve dose adherence. Packaging alone generally provides limited patent protection but can reduce product-quality and supply risks.

References

1. U.S. Food and Drug Administration. (2001). Yasmin-28 tablets: Prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.